ストックスクリーナーアプリを入手
4.57
1.30%
-0.06
プレマーケット:
4.57
Altimmune Inc (ALT) 最新ニュース
Altimmune, Inc. (NASDAQ:ALT) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Altimmune gains on FDA breakthrough designation for MASH therapy - MSN
Altimmune, Inc. Closes $75 Million Registered Direct Offering to Advance Pemvidutide Development for Liver Diseases - Quiver Quantitative
Altimmune, Inc. (ALT) gains analyst support ahead of phase 3 MASH development - MSN
Is Altimmune Inc a strong candidate for buy and hold2025 Growth vs Value & AI Powered Market Entry Ideas - baoquankhu1.vn
Altimmune Sets 2026 Annual Stockholder Meeting Timeline - TipRanks
Altimmune Outlook: Where Pemvidutide Phase 3 Is Heading In 2026 (NASDAQ:ALT) - Seeking Alpha
Forecast Cut: Is Altimmune Inc a strong candidate for buy and holdTake Profit & Smart Swing Trading Techniques - baoquankhu1.vn
Altimmune, Inc. (ALT) Gains Analyst Support Ahead of Phase 3 MASH Development - Insider Monkey
Growth Report: Is Altimmune Inc a strong candidate for buy and holdJuly 2025 Short Interest & Reliable Trade Execution Plans - baoquankhu1.vn
Altimmune stock price ends higher after $75 million deal closes as Vanguard filing adds focus - TechStock²
Altimmune, Inc. (ALT) Stock Analysis: Exploring a 246% Potential Upside in the Biotech Arena - DirectorsTalk Interviews
Altimmune closes $75 million registered direct offering By Investing.com - Investing.com India
Altimmune (NASDAQ:ALT) Trading Up 7.2%Here's What Happened - MarketBeat
Is Altimmune Inc. a potential multi baggerAnalyst Upgrade & High Accuracy Trade Signal Alerts - mfd.ru
Altimmune closes $75 million registered direct offering - Investing.com
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - Benzinga
Biotech Altimmune raises $75M for Phase 3 MASH liver drug trial - Stock Titan
Altimmune (NASDAQ:ALT) Rating Increased to Strong-Buy at Barclays - MarketBeat
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration - Sahm
Altimmune raises $75 million to fund MASH therapy development By Investing.com - Investing.com Nigeria
ALT Stock Surges Toward Sixth Straight Day Of Gains: Retail Bets A Buyout Is On The Horizon - Stocktwits
Altimmune Announces $75 Million Registered Direct Equity Offering - TipRanks
Altimmune Signs Multiple Material Agreements - TradingView
Altimmune: Why Breakthrough Status Isn't A 'Buy' Signal Just Yet (NASDAQ:ALT) - Seeking Alpha
Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
Altimmune prices $75M direct offering - MSN
Altimmune (NASDAQ:ALT) Shares Gap DownHere's Why - MarketBeat
Altimmune Stock Volatility Spurs Investor Attention - StocksToTrade
Altimmune’s Recent Developments and Market Impact - timothysykes.com
Altimmune shares slide after $75 million registered direct offering - MSN
Altimmune stock falls after announcing $75 million direct offering By Investing.com - Investing.com South Africa
Altimmune stock falls after announcing $75 million direct offering - Investing.com
Qorvo, Altimmune, United Microelectronics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session - Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Altimmune Prices $75 Million Registered Direct Offering - marketscreener.com
Biotech Altimmune raises $75M to prepare Phase 3 MASH liver trial - Stock Titan
Altimmune (ALT) Raises $75M to Boost Obesity Drug Pipeline - TipRanks
Altimmune Prices $75 Mln Of Share Offering; Stock Down - Nasdaq
Altimmune (ALT) Prepares for Phase 3 Trial with New Funding - GuruFocus
Altimmune Secures $75M from Institutional Investor in Direct Offering - Intellectia AI
Altimmune (ALT) Secures $75M in Direct Offering to Fund Phase 3 Trial - GuruFocus
Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - The Manila Times
Trend Recap: Will Altimmune Inc stock hit new highs in YEAR - baoquankhu1.vn
Altimmune raises $75 million to fund MASH therapy development - Investing.com
Altimmune, Inc. Announces $75 Million Registered Direct Offering to Support Phase 3 Trial for Pemvidutide - Quiver Quantitative
1.24%
0.19%
大文字化:
|
ボリューム (24 時間):